Shancastle Investments and Orchard Capital increase stakes in Lentitek
Published
Shancastle Investments Limited and Orchard Capital Ventures have increased their holdings in Edinburgh based biotechnology firm Lentitek Ltd. According to the latest confirmation statement (2025-04-05), Shancastle Investments Limited increased its stake by 66 percent, moving from 565 to 938 Ordinary shares. Shancastle is also a shareholder in Arcus Global Limited and Insignia Technologies Limited.
Orchard Capital Ventures increased its position by 58 percent, growing its holding from 565 to 892 Ordinary shares. These changes occurred while Edinburgh Technology Fund remained on the cap table with 1,696 shares. The simultaneous increase in holdings by multiple existing investors may signal a recent round of funding.
Founded in 2019, Lentitek develops proprietary technology to enhance the quality, yield, and compatibility of lentiviral vectors. These vectors are critical for advanced therapies including adoptive cell therapies and gene therapies like CAR-T. The company provides its platform to asset developers through a serviced CRO license model to improve manufacturing efficiency and accessibility for these treatments.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| Increased | SHANCASTLE INVESTMENTS LIMITED | 938 | +66% | ORDINARY 938 |
| Increased | ORCHARD CAPITAL VENTURES | 892 | +58% | ORDINARY 892 |
Current shareholders (3)
| Shareholder | Total shares | Share classes |
|---|---|---|
| EDINBURGH TECHNOLOGY FUND | 1,696 | ORDINARY 1,696 |
| SHANCASTLE INVESTMENTS LIMITED | 938 | ORDINARY 938 |
| ORCHARD CAPITAL VENTURES | 892 | ORDINARY 892 |
Contact the editorial team at [email protected]